Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMPD1 | P17405 | 1/20 | 0.47 |
| ▸ | BRD4 | O60885 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.42 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15684128 | 0.83 | SMPD1 (0.47) | SMPD1BRD4NPC1RAB9AGABRA5 | |
| SCHEMBL25025302 | 0.83 | SMPD1 (0.47) | SMPD1BRD4NPC1RAB9AGABRA5 | |
| SCHEMBL322866 | 0.83 | SMPD1 (0.53) | SMPD1BRD4NPC1RAB9A | |
| SCHEMBL12268217 | 0.83 | SMPD1 (0.47) | SMPD1BRD4NPC1RAB9AGABRA5 | |
| SCHEMBL13520120 | 0.83 | NOTUM (0.51) | SMPD1BRD4NPC1RAB9ANUDT1 | |
| SCHEMBL979239 | 0.83 | SMPD1 (0.44) | SMPD1BRD4 | |
| SCHEMBL28080632 | 0.81 | SMPD1 (0.43) | SMPD1BRD4 | |
| SCHEMBL24578981 | 0.81 | MEN1 (0.44) | SMPD1BRD4NPC1RAB9AMEN1 | |
| SCHEMBL17726575 | 0.81 | BRD4 (0.49) | SMPD1BRD4NPC1RAB9AGABRA5 | |
| SCHEMBL17726200 | 0.80 | SMPD1 (0.53) | SMPD1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9688644-B2 | Synthesis of Tetracyclines and intermediates thereto | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2017-06-27 | — | — | US | disclosed |
| US-9688644-B2 | Synthesis of Tetracyclines and intermediates thereto | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2017-06-27 | — | — | US | disclosed |
| US-20160002183-A1 | SYNTHESIS OF TETRACYCLINES AND INTERMEDIATES THERETO | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2016-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160002183-A1 | SYNTHESIS OF TETRACYCLINES AND INTERMEDIATES THERETO | TECR, TAOK1, TET1 | SMPD1 4740/4885BRD4 2385/4885NPC1 2850/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.